BioSpace News Archive

Aquestive Therapeutics, Inc. announced that the management team will participate in two upcoming investor conferences as follows.

Impel Pharmaceuticals (NASDAQ: IMPL) today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential drug-drug interactions (DDIs) between Trudhesa® (dihydroergotamine [DHE] mesylate) nasal spray (0.725 mg per spray) and orally administered gepant medications.

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated clinical data from the three EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society taking place in National Harbor, Maryland on April 26-30, 2023.

Spero Therapeutics, Inc. announced that Spero’s management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City, on May 2, 2023.

Ardelyx, Inc. announced it will hold a conference call on Wednesday, May 3, 2023, at 4:30 p.m. Eastern Time to discuss first quarter financial results and provide a business update.

Alpha Teknova, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.

QSAM Biosciences Inc. (OTCQB: QSAM) announced today that the European Patent Office (EPO) has allowed a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced its sponsorship of Save Your Tooth Month 2023, a public awareness campaign aimed at promoting the benefits of saving natural teeth through endodontic treatment.

CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, announced topline results from its landmark Synuclein-One Study sponsored by the National Institutes of Health.

Tiziana Life Sciences, Ltd. announced financial results for the twelve months ended December 31, 2022, and provided a corporate update on its lead programs in development.